Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy

Cytokine Growth Factor Rev. 2022 Oct:67:49-57. doi: 10.1016/j.cytogfr.2022.07.004. Epub 2022 Jul 18.

Abstract

Tumor immunotherapy, such as PD-1/PD-L1 blockade, has shown promising clinical efficacy in patients with various types of tumors. However, the response to PD-1/PD-L1 blockade in a majority of malignancies is limited, indicating an urgent need for a deeper understanding of the mechanisms of PD-1/PD-L1 axis-mediated tumor tolerance. As the most abundant immune cells in the tumor stroma, macrophages display multiple phenotypes and functions in response to the stimuli of the tumor microenvironment. PD-1/PD-L1 has been demonstrated to be highly expressed in tumor-associated macrophages (TAMs), and TAM polarization has been shown to be important during tumor progression. In this review, we outline the relationship between TAM PD-1/PD-L1 expression and polarizations, summarize the involvement of M2 TAMs in PD-1/PD-L1-mediated T-cell exhaustion, and discuss improved approaches for overcoming PD-1/PD-L1 blockade resistance by inducing M2/M1 switching of TAMs.

Keywords: Immune checkpoint blockade; Macrophages; PD-1/PD-L1; Polarization; T cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen*
  • Humans
  • Immunotherapy
  • Neoplasms* / therapy
  • Programmed Cell Death 1 Receptor
  • Tumor Microenvironment
  • Tumor-Associated Macrophages

Substances

  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor